This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Stocks John Paulson Is Buying


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Medical device maker Covidien (COV) is another name that Paulson & Co. added to its portfolios in the last quarter. The firm bought 1.8 million shares of the $25 billion company, taking on a $100 million stake in shares at current price levels. While COV has been trading sideways for much of the year, the stock's trajectory has been turning higher since the start of June. That bodes well for Paulson's portfolio in the second-half of 2012.

Covidien's diverse set of healthcare products includes medical devices, imaging systems, and pharmaceuticals; that's positioning that protects COV's sales from getting hit by any big industry speed bumps that could derail an overly concentrated name. Covidien also stands to benefit from the Supreme Court's decision on Obamacare, a move that should help to increase the number of patients who are capable of paying for COV's products. While limited U.S. exposure mitigates the full effect of the ruling on COV's top line, a rising tide should help to lift all ships in the medical device and pharma businesses.

>>5 European Stocks Too Cheap to Ignore

A strong balance sheet and a history of dividend payouts should help to boost returns for COV shareholders, particularly given the sideways bent that shares have been on since January. Because this stock hasn't been on a tear for most of the year, it's not suffering from an overextended valuation. Instead, shares look reasonably cheap right now.

Investors looking for healthcare exposure would do well to follow Paulson's lead in COV.

Covidien shows up on a list of 8 High-Quality Dividend-Paying European Stocks Trading Cheaply.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
VIAB $52.35 2.83%
COV $106.71 -1.26%
CZR $7.99 4.31%
AAPL $118.03 -0.71%
FB $105.41 -0.31%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs